Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients

NCT05894850 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2023-06-01
Last updated
2023-06-08

Condition(s) studied

Artificial IntelligenceSurveillance

Investigational drug(s) / intervention(s)

AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.Manually remind the patients

AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.

AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.

Manually remind the patients: Medical staff remind patients manually .

Study summary

In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system reminding though telephone and message, group B with intelligent surveillance system reminding though message, group C with manual reminder, and group D with natural state. The surveillance among the four groups were compared.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female aged 18 years or older who undergo colonoscopy. Exclusion Criteria: * 1)No pathological result. * 2\) No or invalid contact information. * 3\) The surveillance interval cannot be determined according to the surveillance guidelines, including poor bowel preparation, colorectal cancer or suspicious malignance, surgery or colorectal ESD history, those who fail to complete colonoscopy due to unbearable, pathological indications of not polyps, hamartoma or lymphoma polyps, history of ulcerative colitis, and so on. * 4\) Has participated in other clinical trials, signed the informed consent form and is in the surveillance period of other clinical trials. * 5\) Have drug or alcohol abuse or psychological disorder in the past five years. * 6)Pregnancy. * 7)Not suitable for recruitment after investigator evaluation because of other high-risk conditions.

Primary outcome measure(s)

  • On-time Surveillance Rate — From enrollment to study completion, assessed up to 3 years.
    The numerator is the number of patients with on-time surveillance, and the denominator is the number of all colorectal postpolypectomy patients requiring surveillance.

Trial sites (1)

FacilityCityRegionStatus
Renmin Hospital of Wuhan University Wuhan Hubei
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05894850 on ClinicalTrials.gov ↗ ← All trials in China